CSIMarket


Amylyx Pharmaceuticals Inc   (AMLX)
Other Ticker:  
 

Amylyx Pharmaceuticals Inc

AMLX's Fundamental analysis








Looking into Amylyx Pharmaceuticals Inc growth rates, revenue grew by 29666.09 % in III. Quarter 2023 from the same quarter a year ago. Ranking at No. 4

Major Pharmaceutical Preparations industry recorded deterioration of revenues by -4.74 %

Amylyx Pharmaceuticals Inc realized net income compared to net loss a year ago in III. Quarter 2023

More on AMLX's Growth


Amylyx Pharmaceuticals Inc
realized net loss in trailing twelve months.

Company is currently trading with Price to Cash flow multiple of 4.38 in trailing twelve-month period.
Company
-
PE TTM   
Industry
-
PE TTM    
Company's Price to Sales ratio is at 0.41.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.31.


More on AMLX's Valuation
 
 Total Debt (Millions $) -
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Revenue/Employee (TTM) $ 3,677,775
 Net Income/Employee (TTM) $ 22,950
 Receivable Turnover (TTM) 12.3
 Tangible Book Value (Per Share $) 6.00

Amylyx Pharmaceuticals Inc
realized net loss in trailing twelve months.

Company is currently trading with Price to Cash flow multiple of 4.38 in trailing twelve-month period.
Company
-
PE TTM   
Industry
-
PE TTM    
Company's Price to Sales ratio is at 0.41.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.31.

Amylyx Pharmaceuticals Inc Price to Book Ratio is at 0.29 lower than Indusry Avg. of 74.58. and higher than S&P 500 Avg. of 0.01

More on AMLX's Valuation

  Market Capitalization (Millions $) 121
  Shares Outstanding (Millions) 70
  Employees 80
  Revenues (TTM) (Millions $) 294
  Net Income (TTM) (Millions $) 2
  Cash Flow (TTM) (Millions $) 28
  Capital Exp. (TTM) (Millions $) -2
  Total Debt (Millions $) -
  Dividend TTM ($) 0 $
  Dividend Yield TTM (%) -
  Revenue/Employee (TTM) $ 3,677,775
  Net Income/Employee(TTM) $ 22,950
  Receivable Turnover Ratio (TTM) 12.3
  Tangible Book Value (Per Share $) 6.00

  Market Capitalization (Millions $) 121
  Shares Outstanding (Millions) 70
  Employees 80
  Revenues (TTM) (Millions $) 294
  Net Income (TTM) (Millions $) 2
  Cash Flow (TTM) (Millions $) 28
  Capital Exp. (TTM) (Millions $) -2


    AMLX's Profitability Comparisons
Amylyx Pharmaceuticals Inc faced margin deterioraten, primarily through cost pressure. Operating Margin fell in III. Quarter 2023 to 18.23 % from 20.57 % in II. Quarter.

Amylyx Pharmaceuticals Inc net profit margin of 20.35 % is currently ranking no. 36 in Major Pharmaceutical Preparations industry, ranking no. 66 in Healthcare sector and number 748 in S&P 500.





  Ratio
   Capital Ratio (MRQ) 9.52
  Total Debt to Equity (MRQ) -
  Tangible Leverage Ratio (MRQ) 0.12
  Asset Turnover Ratio (TTM) 0.69
  Inventory Turnover Ratio (TTM) 0.94



Amylyx Pharmaceuticals Inc faced margin deterioraten, primarily through cost pressure. Operating Margin fell in III. Quarter 2023 to 18.23 % from 20.57 % in II. Quarter.

Amylyx Pharmaceuticals Inc net profit margin of 20.35 % is currently ranking no. 36 in Major Pharmaceutical Preparations industry, ranking no. 66 in Healthcare sector and number 748 in S&P 500.

More on AMLX's Key Ratios





Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com